Adaptive will work with NCI's Cancer Therapy Evaluation Program to use its ImmunoSeq platform for biomarker discovery in clinical trials.
The company recently raised $8 million and is looking to partner with other firms interested in antigen discovery and diagnostic development.
The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.
SerImmune is developing an immune mapping technology that uses next-generation sequencing to identify how circulating antibodies pair with antigens.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
Illumina's partnership with the Human Vaccines Project and Vanderbilt looks to crunch data sets billions of times larger than human genome.
The project aims to sequence the immune repertoires of study participants to spur new vaccine and immunotherapy development.
Adaptive aims to commercialize and scale its techniques to identify immune signatures in other infectious diseases, autoimmune disorders, and even cancer.
The single-cell VDJ profiling kit is the first of a suite of immunology products the company plans to launch this year.
CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.
Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.
Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.
In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.